ResearcherUniversity of MissouriActive in the last 2 years
Eric T. Kimchi
Matched on ORCID iD 0000-0002-5046-1142; OpenAlex author ID A5000341566. Sources: ClinicalTrials.gov.
Their work
- Papers
- 7
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2012: 1 trial · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper
Papers 7
- Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. Co-author DOI 10.1016/j.omton.2025.201080↗
- Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16081470↗
- Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy. Co-author DOI 10.3390/cancers16101808↗
- A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance. Co-author DOI 10.1016/j.canlet.2023.216457↗
- Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. Co-author DOI 10.1016/j.tranon.2021.101262↗
- LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.3389/fcell.2021.647387↗
- Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2488-7↗
Trials 1
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Guangfu Li · 6 shared papers, 2021–2025 · strength 1.16
- Paper Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcino… DOI 10.3390/cancers16081470↗
- Paper Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy. DOI 10.3390/cancers16101808↗
- Paper Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. DOI 10.1016/j.omton.2025.201080↗
- Olamide Tosin Olaoba · 3 shared papers, 2024–2025 · strength 0.72
- Paper Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcino… DOI 10.3390/cancers16081470↗
- Paper Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy. DOI 10.3390/cancers16101808↗
- Paper Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. DOI 10.1016/j.omton.2025.201080↗
- Ming Jun Yang · 3 shared papers, 2023–2024 · strength 0.66
- Paper Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcino… DOI 10.3390/cancers16081470↗
- Paper Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy. DOI 10.3390/cancers16101808↗
- Paper A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resist… DOI 10.1016/j.canlet.2023.216457↗
- Kun Cheng · 3 shared papers, 2021–2025 · strength 0.53
- Paper Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. DOI 10.1016/j.omton.2025.201080↗
- Paper A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resist… DOI 10.1016/j.canlet.2023.216457↗
- Paper LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. DOI 10.3389/fcell.2021.647387↗
- Nan Lyu · 2 shared papers, 2023–2025 · strength 0.41
- Paper Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. DOI 10.1016/j.omton.2025.201080↗
- Paper A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resist… DOI 10.1016/j.canlet.2023.216457↗
- Xinjian Liu · 2 shared papers, 2021–2025 · strength 0.35
- Yi Miao · 2 shared papers, 2021–2025 · strength 0.35
- Jussuf T. Kaifi · 3 shared papers, 2014–2022 · strength 0.31
- Paper Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. DOI 10.1016/j.tranon.2021.101262↗
- Paper LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. DOI 10.3389/fcell.2021.647387↗
- Paper Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic ca… DOI 10.1007/s00280-014-2488-7↗
- Ernest Ramsay Camp · 1 shared paper, 2025 · strength 0.24
- Jing Zhou · 1 shared paper, 2023 · strength 0.18
- Chiswili Yves Chabu · 1 shared paper, 2022 · strength 0.15
- Jing Zhou · 1 shared paper, 2022 · strength 0.15
- Hao Yuan · 1 shared paper, 2021 · strength 0.11
- Kuirong Jiang · 1 shared paper, 2021 · strength 0.11
- Chandra Prakash Belani · 1 shared paper, 2014 · strength 0.04
- Yixing Jiang · 1 shared paper, 2014 · strength 0.04
- Niraj Jaysukh Gusani · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.